pGEX-5X-3-SARS-CoV-2-3CL Citations (2)

Originally described in: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors.
Iketani S, Forouhar F, Liu H, Hong SJ, Lin FY, Nair MS, Zask A, Huang Y, Xing L, Stockwell BR, Chavez A, Ho DD Nat Commun. 2021 Apr 1;12(1):2016. doi: 10.1038/s41467-021-22362-2. PubMed Journal

---

Articles Citing pGEX-5X-3-SARS-CoV-2-3CL

Articles
Development of small molecule non-covalent coronavirus 3CL protease inhibitors from DNA-encoded chemical library screening. Liu H, Zask A, Forouhar F, Iketani S, Williams A, Vaz DR, Habashi D, Choi K, Resnick SJ, Hong SJ, Lovett DH, Bai T, Chavez A, Ho DD, Stockwell BR. Nat Commun. 2025 Jan 2;16(1):152. doi: 10.1038/s41467-024-55421-5. PubMed
Pediatric Cardiovascular Multiscale Modeling using a Functional Mock-up Interface. Garven EE, Kung E, Stevens RM, Throckmorton AL. Cardiovasc Eng Technol. 2025 Apr;16(2):202-210. doi: 10.1007/s13239-024-00767-6. Epub 2025 Jan 6. PubMed

If you have published an article using this material, please email us at to have your article added to this page.